Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Servier Russia
A patient with depression occurred within 3 month period after onset of confirmed COVID 19 infection who has already been recommended to initiate antidepressive treatment with agomelatine will be asked to provide a consent to participate in the study and in case of consent is positive the patient will be invited for 3 more visits starting from the date of the inclusion in the study according to clinical practice. Therefore clinical parameters needed for describing effectiveness and tolerability of agomelatine treatment will be prospectively collected at each of these visits. Antidepressive treatment of enrolled outpatients can be modified by investigating psychiatrist or neurologist at any time of the observation if required.
Following visits are planned:
1. Inclusion Visit 0 (V0) - inclusion in the study
2. Follow up Visits 1-2 (V1-V2) - visits at week 2 and week 4 after V0.
3. Final Visit 3 (V3) - visit at week 8 after V0.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Obtained signed informed consent from the patient.
Age of 18-65 years old.
Out-patient with confirmed COVID 19 infection within 3 months period before the date of inclusion.
Confirmed depression with total HAMD-17 score of 8-24 required treatment with antidepressive medicines.
Decision to administer agomelatine preceeds the decision to include a patient in the study.
You may not be if
Current participation in any clinical trial or during 30 day period from inclusion visit.
Suicide risk (accoding clinical evaluation of investigator).
Psychotics symptoms (according clinical evaluation of investigator).
